Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis

Qin, Xue; Peng, Qiliu; Qin, Aiping; Chen, Zhiping; Lin, Liwen; Deng, Yan; Xie, Li; Xu, Juanjuan; Li, Haiwei; Li, Taijie; Li, Shan; Zhao, Jinmin

doi:10.1186/1746-1596-7-136

Diagnostic Pathology

Table 1 General characteristics of individual studies in the meta-analysis of COMT Val158Met polymorphism and breast cancer

From: Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis

Study, year	Country	Ethnicity	No. of cases/controls	BC diagnosis	Matching criteria	Genotyping method	Menopausal status	Control sources	Quality control	HWE⁶(p value)
Lavigne 1997	America	Caucasian	113/114	NR	Age, race	PCR-RFLP	Pre-, Post-	HB	NR	0.862
Thompson 1998	America	Caucasian	281/289	Histologically confirmed	Age, region	PCR-RFLP	Pre-, Post-	PB	NR	0.522
Millikan^a 1998	America	Caucasian	389/379	Histologically confirmed	Age, race	PCR-RFLP	Pre-, Post-	PB	Yes	0.916
Millikan^b 1998	America	Mixed/other	265/263	Histologically confirmed	Age, race	PCR-RFLP	Pre-, Post-	PB	Yes	0.838
Huang 1999	China	Asian	118/125	Pathologically conformed	NR	PCR-RFLP	Pre-, Post-	HB	NR	0.612
Goodman 2001	America	Caucasian	112/113	Histologically confirmed	Age, race	PCR-RFLP	Mixed	PB	Yes	0.788
Mitrunen 2001	Finland	Caucasian	481/480	Histologically confirmed	NR	PCR-RFLP	Pre-, Post-	PB	NR	0.921
Yim 2001	Korea	Asian	163/163	Histopathologically confirmed	Age	PCR-RFLP	Pre-, Post-	HB	Yes	0.004
Jungestrom 2001	Sweden	Caucasian	126/117	NR	Age	PCR-RFLP	Pre-	HB	NR	0.209
Hamajima 2001	Japan	Asian	150/165	Histologically confirmed	NR	PCR-RFLP	Pre-, Post-	HB	NR	0.079
Kocabas 2002	Turkey	Caucasian	84/103	Histologically confirmed	Age	PCR-RFLP	Pre-, Post-	HB	NR	0.227
Comings 2003	America	Caucasian	67/145	NR	Region	PCR-RFLP	Post-	PB	NR	0.335
Wedren 2003	Sweden	Caucasian	1490/1340	NR	Age	DASH	Post-	PB	Yes	0.772
Wu 2003	America	Asian	589/562	NR	Age, race	TaqMan	Mixed	PB	NR	0.646
Tan 2003	China	Asian	250/250	Histopathologically confirmed	Age	PCR-RFLP	Pre-, Post-	HB	NR	0.174
Sazci 2004	Turkey	Caucasian	130/224	Histopathologically confirmed	Age	PCR-RFLP	Pre-	PB	NR	0.000
Dunning 2004	UK	Caucasian	2850/1908	NR	Age, region	TaqMan	Post-	PB	Yes	0.232
Hefler 2004	Austria	Caucasian	391/1698	Histologically confirmed	Age, region	Sequencing	Mixed	HB	Yes	0.577
Ahsan 2004	America	Caucasian	313/262	Histopathologically confirmed	Age	LP	Mixed	FB	Yes	0.108
Modugno 2005	America	Caucasian	250/3950	Histopathologically confirmed	NR	TaqMan	Post-	PB	NR	0.391
Lin 2005	China	Asian	99/366	Pathologically conformed	Age, region	PCR-RFLP	Mixed	PB	Yes	0.972
Lin 2005	China	Asian	87/341	Pathologically conformed	Age, region	PCR-RFLP	Mixed	PB	Yes	0.393
Marchand 2005	America	Mixed/other	1339/1370	NR	Age	PCR-RFLP	Post-	PB	NR	0.109
Wen 2005	China	Asian	1120/1191	Pathologically conformed	Age	PCR-RFLP	Pre-, post-	PB	Yes	0.698
Cheng 2005	China	Asian	496/740	Pathologically conformed	Age	NR	Mixed	HB	Yes	0.006
Gaudet^a 2006	America	Caucasian	1048/1092	Pathologically conformed	Age	MALDI-TOF	Pre-, post-	PB	Yes	0.853
Gaudet^b 2006	Poland	Caucasian	1983/2279	Histopathologically confirmed	Age	TaqMan	Mixed	PB	Yes	0.525
Gallicchio 2006	America	Caucasian	81/1251	Pathologically conformed	NR	TaqMan	Mixed	PB	NR	0.440
Chang 2006	China	Asian	189/321	Histologically confirmed	Age	PCR-RFLP	Mixed	HB	NR	0.068
Onay 2006	Canada	Caucasian	398/372	Pathologically conformed	Age	TaqMan	Pre-	FB	Yes	0.283
Pharoah 2007	UK	Caucasian	2176/2012	NR	NR	TaqMan	Mixed	PB	NR	0.287
Ralph^a 2007	America	Caucasian	1626/3286	NR	Age	TaqMan	Pre-, post-	HB	Yes	0.758
Ralph^b 2007	America	Caucasian	500/1005	NR	Age	TaqMan	Pre-, post-	HB	Yes	0.549
Akisik 2007	Turkey	Caucasian	114/108	NR	Age	PCR-RFLP	Mixed	NR	NR	0.966
Hu 2007	China	Asian	112/110	Pathologically conformed	Age	Sequencing	Pre-, post-	HB	NR	0.252
Takata 2007	America	Mixed/other	325/250	Mammographically examed	Age	PCR-RFLP	Pre-, post-	PB	NR	0.104
Onay^a 2008	Canada	Caucasian	1217/714	Pathologically conformed	Age	TaqMan	Mixed	FB	Yes	0.832
Onay^b 2008	Finland	Caucasian	708/549	Pathologically conformed	Age	TaqMan	Mixed	FB	Yes	0.676
Justenhoven 2008	Germany	Caucasian	606/622	NR	Age	MALDI-TOF MS	Mixed	PB	Yes	0.654
He 2009	America	Caucasian	1212/1683	Pathologically conformed	Age	TaqMan	Mixed	HB	Yes	0.850
Reding 2009	America	Caucasian	891/878	NR	Age	TaqMan	post-	PB	Yes	0.606
GENICA 2009	Germany	Caucasian	3144/5481	Histologically conformed	Age, region	MALDI-TOF MS	post-	PB	Yes	0.094
Yadav 2009	India	Asian	154/166	NR	Region	PCR-RFLP	Pre-, post-	HB	NR	0.570
Shrubsole 2009	China	Asian	1093/1169	Pathologically conformed	Age	PCR-RFLP	Pre-, post-	PB	Yes	—
Sangrajrang 2009	Thailand	Asian	565/486	Histologically conformed	NR	TaqMan	Mixed	HB	Yes	0.610
Mónica 2010	Mexico	Caucasian	91/94	Pathologically conformed	Age, education	PCR-RFLP	Pre-, post-	HB	NR	0.669
Syamala^a 2010	India	Asian	219/367	Histologically conformed	Age	PCR-RFLP	Mixed	PB	NR	0.183
Syamala^b 2010	India	Asian	140/367	Histologically conformed	Age	PCR-RFLP	Mixed	FB	NR	0.183
Peterson 2010	America	Caucasian	1584/1416	Pathologically conformed	Age	TaqMan	Mixed	PB	Yes	0.026
Delort 2010	France	Caucasian	910/1000	Pathologically conformed	Age	TaqMan	Mixed	PB	Yes	0.230
Wang 2011	China	Asian	400/400	Histopathologically conformed	Age	Sequencing	Pre-, post-	PB	Yes	0.389
Naushad 2011	India	Asian	212/233	Histopathologically conformed	NR	PCR-RFLP	Mixed	HB	NR	0.201
Cribb 2011	Canada	Caucasian	207/621	Histopathologically conformed	Age	PCR-RFLP	Mixed	HB	NR	0.208
Cerne 2011	Slovenia	Caucasian	530/270	NR	Age	TaqMan	post-	HB	Yes	0.903
Lajin 2011	Syria	Mixed/other	135/107	Pathologically conformed	Age	PCR-RFLP	Pre-, post-	PB	NR	0.887
Santos 2011	Brazil	Mixed/other	62/62	Pathologically conformed	Age	PCR-RFLP	Pre-, post-	PB	NR	—

PB Population-based FB family-based, HB hospital-based, HWE Hardy–Weinberg equilibrium, NR not reported, Pre- premenopausal, Post- postmenopausal, PCR-RFLP PCR-based restriction fragment length polymorphism, MALDI-TOF MS matrix assisted laser desorption/ionization time-of-flight mass spectrometry, LP Luorescence polarization.
^{a, b} They were two different case–control studies in one publication.

Back to article page

ISSN: 1746-1596

Contact us

Submission enquiries: journalsubmissions@springernature.com